NeuroDerm Ltd. (Nasdaq: NDRM) reported positive results from a Phase IIa
study of ND0612H and ND0612L in treating Parkinson's Disease. Shares of the pharmaceutical more than doubled by leaping $7.28 to $13.46.
NeuroDerm reports positive study results
December 30, 2014 at 12:53 PM EST
